Clinical trials · Michigan
Focal Segmental Glomerulosclerosis clinical trials in Michigan
We’re tracking 10 recruiting focal segmental glomerulosclerosis studies with a site in Michigan — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07268638RecruitingPhase 2
Study of praliciguat for focal segmental glomerulosclerosis
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
Livonia, MichiganAges 18 years+ - NCT07220083RecruitingPhase 3
A study of BI 764198 for people with FSGS kidney disease
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
Detroit, MichiganAges 12 years+ - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Ann Arbor, MichiganAges 16–75 - NCT05650619Recruiting
Study of return of kidney disease after transplant
This observational study looks at people with FSGS or minimal change disease whose kidney disease came back after a transplant. The goal is to better understand patterns of recurrence and what factors may be linked to it.
Ann Arbor, MichiganAges Any age - NCT02235857Recruiting
Device treatment study for children with focal segmental kidney scarring
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
Grand Rapids, MichiganAges Up to 21 years - NCT04065438Recruiting
Study of a blood-filter treatment for FSGS not responding to meds
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
Grand Rapids, MichiganAges Up to 75 years - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Ann Arbor, MichiganAges 1–80 - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Ann Arbor, MichiganAges 1–17 - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+ - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
Ann Arbor, MichiganAges Up to 80 years
Focal Segmental Glomerulosclerosis trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting focal segmental glomerulosclerosis studies listed above.
- University of Michigan · 6 studies
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · 2 studies
- Henry Ford Health
- Investigator Site #10
- Investigator Site #15
- Paragon Health Nephrology Center - Kalamazoo
- St. Clair Nephrology Research, LLC - Shelby Township
What taking part in a focal segmental glomerulosclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Focal Segmental Glomerulosclerosis trials in other states
Common questions
- Are there focal segmental glomerulosclerosis clinical trials in Michigan?
- Yes. We're currently tracking 10 recruiting focal segmental glomerulosclerosis studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a focal segmental glomerulosclerosis study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a focal segmental glomerulosclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New focal segmental glomerulosclerosis studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.